BEACON · Novel molecular beacon technologies for the study of hiv-1 and other infectious agents
6РП — Действия „Мария Кюри“
- Период
- —
- Финансиране от ЕС
- 80 000 €
- Участници
- 1
- Схема
- IRG
Линиите свързват координатора с партньорите.
Накратко на български
Молекулярните „маяци“ (специални синтетични сонди) се използват за откриване на HIV-1 и други инфекции чрез разпознаване на точни генетични последователности. Това помага за проследяване на лекарствената резистентност на вируса и по-добро предвиждане на ефекта от лечението.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Final Activity Report Summary - BEACON (Novel molecular beacon technologies for the study of hiv-1 and other infectious agents)
The original scope of the project was to investigate the use of molecular beacon technologies in other infectious agents aiming to develop a unique approach for a class of challenging problems in human genetics and infectious diseases. Molecular beacons are synthetic hairpin-shaped nucleic acid probes that undergo a fluorogenic conformational change upon binding to their nucleotide-specific target. As a consequence of their unique architecture, they are extraordinarily specific even in the presence of genetically quasi-similar targets. A single nucleotide mismatch between the probe sequence and the target sequence prevents hybridization. Molecular beacons can be labelled with differently coloured fluorophores, enabling multiplex, homogeneous amplification assays to be carried out in real-time in sealed reaction tubes. Among the applications are the detection of infectious viral and microbial agents in clinical and environmental samples, the quantitative assessment of gene expression, and the determination of genotypes in human alleles associated with human disease. The proposal dealt with the investigation of 1) the role of the concentration of HIV-1 DNA in peripheral blood mononuclear cells (cellular viral load), in predicting the virological response to treatment 2) the determination if single-dose neviparine (NVP) used to prevent HIV-1 perinatal transmission is associated with the selection of a higher frequency of resistance mutations in HIV-1 infected mothers and 3) the HIV-1 genetic diversity and determination of the molecular epidemiology and spread of drug resistance of HIV-1 infection in Cyprus. Concerning the overall aims set in the proposal, we have succeded in establishing a national infrastructure in collaboration with the AIDS Department of the Ministry of Health and the Gregorian AIDS Clinic of well trained, a quality controlled reference HIV virology laboratory in the University of Cyprus for studies associated with the HIV molecular epidemiology and genotypic resistance in Cyprus. We have also managed to enrol Cyprus in the European network, EuropeHIVResistance, which aims to implement a European strategy to prevent transmission of resistant HIV-1 strains in close collaboration with a network of the Associated States of Europe. In addition we have developed a Cypriot database and viral panels of HIV-1 strains, which may be used for development of specialized diagnostic assays, HIV antiretroviral compounds and vaccines. Furthermore, genotypic drug resistance analyses were performed on drug-naive patients in the course of molecular analyses of the Protease and Reverse Transcriptase genes.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The proposed research concerns molecular beacon technology in infectious diseases in general and HIV disease in particular. This is a well-timed area with numerous possible applications and where fundamental technologies in biomedical sciences are limiting and novel technologies are increasingly in demand.The first overall goal of this initial research project is to investigate the role of HIV-1 cellular viral load and antiretroviral drug-resistant variants on the antiretroviral treatment of HIV-1-infected individuals by using novel quantitative HIV-1 diagnostic assays. The assays have been previously constructed and evaluated in our laboratory and are based on molecular beacon and allele discriminating real-time PCR technologies that is the primary technology of our laboratory.Our first aim involves investigating the implications of the concentration of HIV-1 DNA in peripheral blood mononuclear cell PBMC) samples ('HIV-1 cellular Viral Load') in predicting the virological response to antiretroviral therapy. In the second aim, we will quantify minor populations of HIV-1 drug resistant strains on mother-to-infant HIV-1 cohorts.The results of the proposed studies will have a direct impact on the clinical care of HIV-1-infected individuals including Cypriot patients. The second goal is to investigate the phylogenic (subtype) distribution and spread of antiretroviral drug-resistance of HIV-1 strains from recent and long-standing patients in Cyprus.It is hoped that the grant support of the Marie Curie International Reintegration Grant will allow the principal investigator to establish a new research laboratory in the University of Cyprus in the best possible conditions and initiate my research activities.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITY OF CYPRUS · NICOSIAКоординаторКипър
Връзки
Данни: CORDIS, © Европейски съюз